As a service to our authors and readers, this journal provides supporting information supplied by the authors. Such materials are peer reviewed and may be re-organized for online delivery, but are not copy-edited or typeset. Technical support issues arising from supporting information (other than missing files) should be addressed to the authors.

emmm201302625.reviewer_comments.pdfPDF document933KReview Process File
emmm201302625-sm-0002-SuppFigs-S1.pdfPDF document1875K

Figure S1. A. Validation of Ret antibody for immunohistochemical (IHC) staining of paraffin sections.

Figure S2. A. Western bot (WB) analysis on lysates from MCF7/Aro, MCF7 and T47D cells was carried out with a Ret antibody (anti-human Ret antibody from Cell Signalling) in the upper panels.

Figure S3. A. Microarray slides were co-hybridized with cDNA from 6-day treated MCF7/Aro cells cultured in the 6 indicated conditions (as in Fig 2F).

Figure S4. A. MCF7 cells were pre-incubated with DMSO or NVP-AST487 (100 nM), then treated 15 min with IL6 (100 ng/ml) or GDNF (10 ng/ml).

Figure S5. A. Groups of J110-tumour bearing mice were randomized and treated once daily with vehicle (10%EtOH in corn oil) or tamoxifen (100 µg/day) for 3 weeks.

Figure S6. A, B. Tumours from mice treated as described in Fig 5C were harvested 8 hours after the final treatment.

Table S1. Correlation of Ret-score with established clinical and histopathological parameters of breast cancer patients.

Table S2. Correlation of Ret score with molecular subtypes of the analysed breast cancer patients.

Please note: Wiley Blackwell is not responsible for the content or functionality of any supporting information supplied by the authors. Any queries (other than missing content) should be directed to the corresponding author for the article.